Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice

Adam Giermasz, Marcin Makowski, Dominika Nowis, Ahmad Jalili, M. A J Malgorzata, Anna Dabrowska, Anna Czajka, Marek Jakobisiak, Jakub Golab

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of tumor cells and have also recently gained acceptance as potential anticancer agents. In this study we observed an increased expression of mTNFα in tumor tissues in mice treated with butyrate prodrug tributyrin. Since in in vitro experiments we observed a potentiating effects of TNFα and actinomycin D on B16F10 cells and also a synergistic interaction was previously claimed between those agents, we investigated the anti-tumor activity of the combination therapy with butyrate and actinomycin D in the B16F10 melanoma model in mice. The combination of the drugs resulted in a strongly potentiated tumor growth retardation in melanoma bearing mice. However the B16F10 cells in vitro did not produce any detectable amounts of TNFα. The presented data strongly suggest that one of the mechanism of this successful drug combination could depend on the interaction of the actinomycin D with butyrate-induced TNFα produced by stromal or tumor infiltrating immune cells. The results illustrate also the possible application of this combination in cancer therapy.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalOncology Reports
Volume9
Issue number1
StatePublished - Jan 2002
Externally publishedYes

Fingerprint

Butyrates
Dactinomycin
Melanoma
Neoplasms
Drug Combinations
Butyric Acid
Prodrugs
Antineoplastic Agents
Apoptosis
Therapeutics
Growth

Keywords

  • Actinomycin D
  • Butyrate
  • Melanoma
  • Mouse
  • TNFα

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Giermasz, A., Makowski, M., Nowis, D., Jalili, A., Malgorzata, M. A. J., Dabrowska, A., ... Golab, J. (2002). Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncology Reports, 9(1), 199-203.

Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. / Giermasz, Adam; Makowski, Marcin; Nowis, Dominika; Jalili, Ahmad; Malgorzata, M. A J; Dabrowska, Anna; Czajka, Anna; Jakobisiak, Marek; Golab, Jakub.

In: Oncology Reports, Vol. 9, No. 1, 01.2002, p. 199-203.

Research output: Contribution to journalArticle

Giermasz, A, Makowski, M, Nowis, D, Jalili, A, Malgorzata, MAJ, Dabrowska, A, Czajka, A, Jakobisiak, M & Golab, J 2002, 'Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice', Oncology Reports, vol. 9, no. 1, pp. 199-203.
Giermasz A, Makowski M, Nowis D, Jalili A, Malgorzata MAJ, Dabrowska A et al. Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncology Reports. 2002 Jan;9(1):199-203.
Giermasz, Adam ; Makowski, Marcin ; Nowis, Dominika ; Jalili, Ahmad ; Malgorzata, M. A J ; Dabrowska, Anna ; Czajka, Anna ; Jakobisiak, Marek ; Golab, Jakub. / Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. In: Oncology Reports. 2002 ; Vol. 9, No. 1. pp. 199-203.
@article{03f0abed9cdb4c99877b53c89705cd2d,
title = "Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice",
abstract = "Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of tumor cells and have also recently gained acceptance as potential anticancer agents. In this study we observed an increased expression of mTNFα in tumor tissues in mice treated with butyrate prodrug tributyrin. Since in in vitro experiments we observed a potentiating effects of TNFα and actinomycin D on B16F10 cells and also a synergistic interaction was previously claimed between those agents, we investigated the anti-tumor activity of the combination therapy with butyrate and actinomycin D in the B16F10 melanoma model in mice. The combination of the drugs resulted in a strongly potentiated tumor growth retardation in melanoma bearing mice. However the B16F10 cells in vitro did not produce any detectable amounts of TNFα. The presented data strongly suggest that one of the mechanism of this successful drug combination could depend on the interaction of the actinomycin D with butyrate-induced TNFα produced by stromal or tumor infiltrating immune cells. The results illustrate also the possible application of this combination in cancer therapy.",
keywords = "Actinomycin D, Butyrate, Melanoma, Mouse, TNFα",
author = "Adam Giermasz and Marcin Makowski and Dominika Nowis and Ahmad Jalili and Malgorzata, {M. A J} and Anna Dabrowska and Anna Czajka and Marek Jakobisiak and Jakub Golab",
year = "2002",
month = "1",
language = "English (US)",
volume = "9",
pages = "199--203",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice

AU - Giermasz, Adam

AU - Makowski, Marcin

AU - Nowis, Dominika

AU - Jalili, Ahmad

AU - Malgorzata, M. A J

AU - Dabrowska, Anna

AU - Czajka, Anna

AU - Jakobisiak, Marek

AU - Golab, Jakub

PY - 2002/1

Y1 - 2002/1

N2 - Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of tumor cells and have also recently gained acceptance as potential anticancer agents. In this study we observed an increased expression of mTNFα in tumor tissues in mice treated with butyrate prodrug tributyrin. Since in in vitro experiments we observed a potentiating effects of TNFα and actinomycin D on B16F10 cells and also a synergistic interaction was previously claimed between those agents, we investigated the anti-tumor activity of the combination therapy with butyrate and actinomycin D in the B16F10 melanoma model in mice. The combination of the drugs resulted in a strongly potentiated tumor growth retardation in melanoma bearing mice. However the B16F10 cells in vitro did not produce any detectable amounts of TNFα. The presented data strongly suggest that one of the mechanism of this successful drug combination could depend on the interaction of the actinomycin D with butyrate-induced TNFα produced by stromal or tumor infiltrating immune cells. The results illustrate also the possible application of this combination in cancer therapy.

AB - Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of tumor cells and have also recently gained acceptance as potential anticancer agents. In this study we observed an increased expression of mTNFα in tumor tissues in mice treated with butyrate prodrug tributyrin. Since in in vitro experiments we observed a potentiating effects of TNFα and actinomycin D on B16F10 cells and also a synergistic interaction was previously claimed between those agents, we investigated the anti-tumor activity of the combination therapy with butyrate and actinomycin D in the B16F10 melanoma model in mice. The combination of the drugs resulted in a strongly potentiated tumor growth retardation in melanoma bearing mice. However the B16F10 cells in vitro did not produce any detectable amounts of TNFα. The presented data strongly suggest that one of the mechanism of this successful drug combination could depend on the interaction of the actinomycin D with butyrate-induced TNFα produced by stromal or tumor infiltrating immune cells. The results illustrate also the possible application of this combination in cancer therapy.

KW - Actinomycin D

KW - Butyrate

KW - Melanoma

KW - Mouse

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=0036134016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036134016&partnerID=8YFLogxK

M3 - Article

C2 - 11748483

AN - SCOPUS:0036134016

VL - 9

SP - 199

EP - 203

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -